Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients

Volume 22, Issue 2, February 2021, Pages 565-571

Aziati Azwari Annuar; Ravindran Ankathil; Nazihah Mohd Yunus; Azlan Husin; Nur Shafawati Ab Rajab; Ahmad Aizat Abdul Aziz; Mohd Ismail Ibrahim; Sarina Sulong

• View Article
• PDF 314.47 K

Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role

Volume 20, Issue 12, December 2019, Pages 3689-3695

Ikhwan Rinaldi; Ary Harryanto Reksodiputro; Sri Widia Jusman; Alida Harahap; Rianto Setiabudy; Septelia Inawati Wanandi; Karmel Tambunan; Catharina Suharti

• View Article
• PDF 320.67 K

Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative Study

Volume 18, Issue 7, July 2017, Pages 1925-1930

Yik-Ming Lim; Wei-Lerk Eng; Huan-Keat Chan

• View Article
• PDF 235.58 K

Clinical Observations on Treatment for Chinese Patients with Gastrointestinal Stromal Tumors

Volume 16, Issue 12, December 2015, Pages 5111-5113

• View Article
• PDF 322.15 K